Crixivan
Product Images NDC 16590-064

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Crixivan (NDC 16590-064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Crixivan 400 mg Label Image (Crixivan 400 mg Label 16590)

CRIXIVAN 400 mg capsules label shows a 90-count bottle by STAT Rx USA LLC. The label states it is generic for indinavir sulfate 500 mg, with each capsule containing 400 mg indinavir 400 mg. The manufacturer is Merck & Co., Inc. with an address in Whitehouse Station, NJ. The label includes caution, storage instructions, and a lot number with expiration details.*

FDA Label Image

Image Of Indinavir Sulfate Chemical Structure (Crixivan 01)

Chemical structure of the active ingredient in CRIXIVAN, as shown in the image. The diagram depicts the molecular structure with various chemical groups and bonds, alongside the presence of a sulfate (H2SO4) component.*

FDA Label Image

Image Of Study Actg 320 Figure 1 (Crixivan 02)

A line graph comparing the proportion of patients over study weeks (0, 8, 24, 40) between two groups: Indinavir + Zidovudine + Lamivudine and Zidovudine + Lamivudine. The graph shows higher patient proportions in the Indinavir combination group across all time points, with data counts appearing below for each group at the respective study weeks.*

FDA Label Image

Image Of Study Actg 320 Figure 2 (Crixivan 03)

A line graph showing CD4 cell count change over study weeks (0 to 24) for two treatment groups: Indinavir + Zidovudine + Lamivudine, and Zidovudine + Lamivudine. The graph tracks cell count change in cells/mm3, with the combination including Indinavir showing greater increases over time. Below the graph are participant counts for each group at weeks 0, 4, 8, and 24.*

FDA Label Image

Image Of Study 028 Figure 3 (Crixivan 04)

A line graph showing the proportion of patients over a 48-week study period comparing three groups: Indinavir plus Zidovudine, Indinavir alone, and Zidovudine alone. The X-axis represents study weeks from 0 to 48, and the Y-axis shows the proportion of patients from 0.0 to 1.0. The graph indicates higher proportions for the Indinavir-containing groups compared to Zidovudine alone. A table below the graph lists patient numbers (N) for each group at different time points.*

FDA Label Image

Image Of Study 028 Figure 4 (Crixivan 05)

A line graph showing CD4 cell count changes (cells/mm3) over 24 study weeks for three groups: Indinavir + Zidovudine, Indinavir alone, and Zidovudine alone. The graph includes a legend and subject count numbers for each group at baseline and week 24.*

FDA Label Image

Image Of Study 035 Figure 5 (Crixivan 06)

Line graph showing RNA change (log10 copies/mL) over 24 weeks for three treatment groups: Indinavir plus Zidovudine and Lamivudine, Indinavir alone, and Zidovudine plus Lamivudine. The graph includes study week on the x-axis and RNA change on the y-axis, with a table below showing sample sizes for each group at various time points.*

FDA Label Image

Image Of Study 035 Figure 6 (Crixivan 07)

A line graph showing the proportion of patients over study weeks (0 to 24) for three treatment groups: Indinavir + Zidovudine + Lamivudine, Indinavir alone, and Zidovudine + Lamivudine. The graph indicates changes in patient proportions for each group across the study duration, with the combination therapy group showing the highest proportion by week 24.*

FDA Label Image

Image Of Study 035 Figure 7 (Crixivan 08)

A line graph showing CD4 cell count changes (cells/mm³) over a 24-week study, comparing three treatment groups: Indinavir with Zidovudine and Lamivudine, Indinavir alone, and Zidovudine with Lamivudine. The x-axis represents study weeks, and the y-axis shows CD4 cell count change. A data table below the graph lists participant numbers at weeks 0, 12, and 24 for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.